Gene · 84790
TUBA1C: tubulin alpha 1c
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. TUBA1C: tubulin alpha 1c. Genes, record 84790. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/84790
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9BQE3 | Tubulin alpha-1C chain | 449 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents58
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 4046 | Q9BQE3 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4770 | Q9BQE3 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 4046 | Q9BQE3 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 4770 | Q9BQE3 | Espacenet |
| JP 2023516705 A | 2023-04-20 | 101 | Q9BQE3 | Espacenet |
| JP 2023516705 A | 2023-04-20 | 102 | Q9BQE3 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 5205 | Q9BQE3 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 93551 | Q9BQE3 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 196522 | Q9BQE3 | Espacenet |
| WO 2021175788 A1 | 2021-09-10 | 101 | Q9BQE3 | Espacenet |
1 to 10 of 58
See all 58 patentsDrugs90
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AGS-16C3F | CHEMBL4594455 | Tubulin disrupting agent | DISRUPTING AGENT | ChEMBL |
| ANETUMAB RAVTANSINE | CHEMBL2109629 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANG1005 | CHEMBL1089636 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANVATABART OPADOTIN | CHEMBL4297892 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| APRUTUMAB IXADOTIN | CHEMBL4650293 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ASG-5ME | CHEMBL2109574 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AVE-9633 | CHEMBL2109266 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AZINTUXIZUMAB VEDOTIN | CHEMBL4297859 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| BELANTAMAB MAFODOTIN | CHEMBL4298209 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| BIIB-015 | CHEMBL2109575 | Tubulin inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 90
See all 90 drugsTrials8,728
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | PACLITAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07602907 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601737 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601178 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07599163 | PACLITAXEL | ClinicalTrials.gov | ||
| NCT07595770 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07594548 | PACLITAXEL | PHASE1 | ClinicalTrials.gov | |
| NCT07591467 | DOCETAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07589972 | VINORELBINE | ClinicalTrials.gov | ||
| NCT07588698 | VINCRISTINE SULFATE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 8,728
See all 8,728 trialsNIH grants664
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TUBA1C papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 7 | 2025 |
| P20GM103446 | Delaware INBRE | 2 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 2 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 2 | 2025 |
| P30CA030199 | Cancer Center Support Grant (CCSG) | 2 | 2025 |
| P30CA062203 | Cancer Center Support Grant | 2 | 2025 |
| P30CA071789 | University of Hawaii Cancer Center CCSG | 2 | 2025 |
| P50CA097186 | The Pacific Northwest Prostate Cancer SPORE | 2 | 2025 |
| P50CA116201 | Mayo Clinic Breast Cancer SPORE | 2 | 2025 |
1 to 10 of 664Source NIH's project files
See all 664 nih grantsPapers852
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Machine learning identifies ac4C-related prognostic signature and TUBA1C as therapeutic target in COAD. | Mamm Genome | 2026 | 42693326 | PubTator, text mining | PubMed |
| Common Molecular Mechanisms and Candidate Drug Targets in Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease. | J Vis Exp | 2026 | 42612061 | PubTator, text mining | PubMed |
| Proteomic and metabolomic analysis of human follicular fluid from follicles with different diameters. | Front Cell Dev Biol | 2026 | 42597911 | PubTator, text mining | PubMed |
| An externally validated lactylation-associated prognostic signature for overall survival prediction in lung adenocarcinoma identifies TUBA1C as a candidate gene. | Transl Cancer Res | 2026 | 42591440 | PubTator, text mining | PubMed |
| XGBoost-SHAP Interpretable Modeling Identifies and Validates an Eight-Gene Biomarker for Hepatic Encephalopathy Risk Prediction in Cirrhosis. | Int J Mol Sci | 2026 | 42589578 | PubTator, text mining | PubMed |
| Glycosylation-related gene risk model and functional validation of OSTC and TUBA1C in lung adenocarcinoma. | Respir Res | 2026 | 42464299 | PubTator, text mining | PubMed |
| Identification of potential vinorelbine-associated prognostic genes in breast cancer through integrative bioinformatics and experimental validation. | Front Oncol | 2026 | 42434754 | PubTator, text mining | PubMed |
| Machine learning-based programmed cell death gene signature for prognosis and drug sensitivity in breast cancer. | Oncol Lett | 2026 | 42027644 | PubTator, text mining | PubMed |
| Lactate-Induced Lactylation Enhances BMAL1 Transcription and Nuclear Translocation, Promoting Bevacizumab Resistance in Glioblastoma through VEGFA. | Clin Cancer Res | 2026 | 41995718 | PubTator, text mining | PubMed |
| Transcriptional Modulation of Infertility-Associated Genes Following Chlamydia trachomatis Infection in Human Fallopian Tube Mesenchymal Cells: In Silico Study. | Genes (Basel) | 2026 | 41898836 | PubTator, text mining | PubMed |
1 to 10 of 852
See all 852 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/84790
GET https://conductscience.org/api/genes/v1/84790/patents?page=2